Advertisement

Epilepsien: Medikamentöse Therapie

  • Andreas Schulze-BonhageEmail author
Living reference work entry
  • 51 Downloads
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Nach Auftreten zweier epileptischer Anfälle oder eines Anfalls bei Vorliegen bildgebender oder elektroenzephalografischer Risikofaktoren für weitere Anfälle besteht die Indikation zur medikamentösen Anfallsprophylaxe. Die Pharmakotherapie von Epilepsien erzielt bei zwei von drei Patienten eine anhaltende Anfallskontrolle. Moderne Antiepileptika ermöglichen auch in Kombination eine gut verträgliche und interaktionsarme Behandlung ohne negative Langzeitbehandlungsfolgen. Bei sich abzeichnender Pharmakoresistenz ist eine frühe Vorstellung an Epilepsiezentren zur Diagnosesicherung und/oder Evaluation nichtmedikamentöser Behandlungsoptionen erforderlich.

Literatur

  1. Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, Resor SR Jr, Hirsch LJ (2007) Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68:1701–1709CrossRefGoogle Scholar
  2. Beghi E, Gatti G, Tonini C et al (2003) Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicenter, randomized, pragmatic, controlled trial. Epilepsy Res 57:1–13CrossRefGoogle Scholar
  3. Berg AT, Shinnar S (1994) Relapse following discontinuation of antiepileptic drugs: a a meta-analysis. Neurology 44:601–608CrossRefGoogle Scholar
  4. Birbeck GL, Hays RD, Cui X, Vickrey BG (2002) Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 43(5):535–8Google Scholar
  5. Brodie MJ, Yuen AW (1997) Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 26:423–432CrossRefGoogle Scholar
  6. Canevini MP, Mai R, DiMarco C et al (1992) Juvenile myoclonic epilepsy of Janz: clinical observations in 60 patients. Seizure 1:291–298CrossRefGoogle Scholar
  7. Chadwick D (1991) Randomized trial on antiepileptic drug withdrawal in patients in remission. Lancet 337:1175–1181Google Scholar
  8. Delgado-Escueta AV, Enrile-Bacsal F (1984) Juvenile myoclonic epilepsy of Janz. Neurology 34:285–294CrossRefGoogle Scholar
  9. Döring J, Syrbe S (2019) Neue Entwicklungen in der genetischen Grundlage kortikaler Malformationen. Z Epileptol 32:303–310. https://doi.org/10.1007/s10309-019-0266-6
  10. Grosso S, Galimberti D, Vezzani P et al (2005) Course and outcome of childhood epilepsy: evolution and prognostic factors. Epilepsia 46:1796–1801CrossRefGoogle Scholar
  11. Hughes DM, Bonnett LJ, Czanner G, Komárek A, Marson AG, García-Fiñana M (2018) Identification of patients who will not achieve seizure remission within 5 years on AEDs. Neurology 91:e2035–e2044CrossRefGoogle Scholar
  12. Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314–319CrossRefGoogle Scholar
  13. Kwan P, Arzomanoglou A, Bert AT, Brodie M, Hauser A, Mathern G et al (2010) Definition of drug-resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51:1069–1077CrossRefGoogle Scholar
  14. Kwan P, Schachter SC, Brodie MJ (2011) Drug-resistant epilepsy. N Engl J Med 365:919–926CrossRefGoogle Scholar
  15. Lang JD, Kostev K, Onugoren MD, Gollwitzer S, Graf W, Müller T, Olmes DG, Hamer HM (2018) Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: a nationwide study of prescription data in Germany. Ann Neurol 84:918–925CrossRefGoogle Scholar
  16. Laville F, Montana M, Roux N, Rathelot P, Giorgi R, Vanelle P (2018) Factors limiting adherence to antiepileptic treatment: a French online patient survey. J Clin Pharm Ther 43:73–79CrossRefGoogle Scholar
  17. Lee BI, No SK, Yi SD et al (2018) Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy. Seizure 55:17–24CrossRefGoogle Scholar
  18. Lee BI, Park KM, Kim SE, Heo K (2019) Clinical opinion: earlier employment of polytherapy in sequential pharmacotherapy of epilepsy. Epilepsy Res 156:106165CrossRefGoogle Scholar
  19. Lossius MI, Hessen E, Mowinckel P et al (2008) Consequences of antiepileptic drug withdrawal : a randomized, double-blind study (Akershus Study). Epilepsia 49:455–463CrossRefGoogle Scholar
  20. Marson AG, Al-Kharusi AM, Alwaidh M et al (2007a) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369:1000–1015CrossRefGoogle Scholar
  21. Marson AG, Al-Kharusi AM, Alwaidh M et al (2007b) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369:1016–1026CrossRefGoogle Scholar
  22. Meador KJ, Baker GA, Browning N et al (2014) Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study Group. JAMA Pediatr 168:729–736CrossRefGoogle Scholar
  23. Mielke H, Meissner S, Wagner K, Joos A, Schulze-Bonhage A (2020) Which seizure elements do patients memorize? A comparison of history and seizure documentation. Epilepsia, im DruckGoogle Scholar
  24. Ryther RC, Wong M (2012) Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptigenic, and epileptostatic therapy. Curr Neurol Sci Rep 12:410–218Google Scholar
  25. Sake JK, Hebert D, Isojärvi J, Doty P, De Backer M, Davies K, Eggert-Formella A, Zackheim J (2010) A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 24:1055–1068CrossRefGoogle Scholar
  26. Scheffer IE, Berkovic S, Capovilla G et al (2017 Apr) ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology. Epilepsia 58(4):512–521.  https://doi.org/10.1111/epi.13709CrossRefPubMedPubMedCentralGoogle Scholar
  27. Schiller Y, Najjar Y (2008) Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 70:54–65Google Scholar
  28. Schmeiser B, Steinhoff BJ, Schulze-Bonhage A (2018) Does early postoperative drug regimen impact seizure control in patients undergoing temporal lobe resections? J Neurol 265:500–509CrossRefGoogle Scholar
  29. Schulze-Bonhage A (2017) A 2017 review of pharmacotherapy for treating focal epilepsy: where are we now and how will treatment develop? Expert Opin Pharmacother 18:1845–1853CrossRefGoogle Scholar
  30. Schulze-Bonhage A (2019a) Orphan drugs in der Epileptologie. Z EpileptologieGoogle Scholar
  31. Schulze-Bonhage A (2019b) Epileptogenesis in symptomatic Epilepsy. In: Shorvon S, Guerrini R, Schachter S, Trinka E (Hrsg) The Causes of Epilepsy, 2. Aufl. Cambridge University Press, Cambridge, S 35–45Google Scholar
  32. Schulze-Bonhage A, Hintz M (2015) Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability. Patient Prefer Adherence 9:1143–1151CrossRefGoogle Scholar
  33. Schulze-Bonhage A, Böttcher S, Glasstetter M, Epitashvili N, Bruno E, Richardson M, Laerhoven KV (2019) Dümpelmann M. Mobiles Anfallsmonitoring bei Epilepsiepatienten. Nervenarzt.  https://doi.org/10.1007/s00115-019-00822-x. Z Epileptol 32:277–285.  https://doi.org/10.1007/s10309-019-0274-6
  34. Semah F, Picot MC, Adam C et al (1998) Ist he underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 51:1256–1262CrossRefGoogle Scholar
  35. Specchio LM, Tramacere I, La Neve A, Beghi E (2002) Discontinuing antiepileptic drugs in patients who are seizure-free on monotherapy. J Neurol Neurosurg Psychiatry 72:22–22CrossRefGoogle Scholar
  36. Spooner CG, Berkovic SF, Mitchell LA, Wrennall JA, Harvey AS (2006) New-onset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome. Neurology 67:2147–2153CrossRefGoogle Scholar
  37. Tomson T, Battino D, Bonizzoni E et al (2016) Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP. Epilepsia 57:e173–e177CrossRefGoogle Scholar
  38. Tomson T, Battino D, Bonizzoni E et al (2018) Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 17:530–538CrossRefGoogle Scholar
  39. Tomson T, Battino D, Bonizzoni E et al (2019) Declining malformation rates with changed antiepileptic drug prescribing: an observational study. Neurology 93:e831–e840CrossRefGoogle Scholar
  40. Vajda FJE, O’Brien TJ, Graham JE et al (2019) Valproate-associated foetal malformations-rates of occurrence, risks in attempted avoidance. Acta Neurol Scand 139:42–48CrossRefGoogle Scholar
  41. Williams J, Lawthom C, Dunstan FD, Dawson TP, Kerr MP, Wilson JF (2006) Smith PE Variability of antiepileptic medication taking behaviour in sudden unexplained death in epilepsy: hair analysis at autopsy. J Neurol Neurosurg Psychiatry 77:481–484CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2020

Authors and Affiliations

  1. 1.EpilepsiezentrumUniversitätsklinikum FreiburgFreiburgDeutschland

Personalised recommendations